Free Trial
NASDAQ:CGON

CG Oncology Q2 2025 Earnings Results & Report

CG Oncology logo
$71.31 +1.16 (+1.65%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CG Oncology missed analyst earnings expectations in its Q2 2025 results, released August 8, 2025. The company reported EPS of -$0.54 versus the -$0.49 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

CG Oncology EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

CG Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$109 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

CG Oncology Q2 2025 Earnings FAQ

CG Oncology (NASDAQ:CGON) reported earnings of -$0.54 per share for Q2 2025, missing the consensus estimate of -$0.49. The report was announced on Friday, August 8, 2025.

CG Oncology Earnings Headlines

CG Oncology FY2026 Earnings Forecast Lifted by HC Wainwright
CG Oncology (NASDAQ:CGON) Stock Price Target Cut by Guggenheim
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
CG Oncology Gains on Q3 Results
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON) is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products. Its clinical development program includes studies of cretostimogene alone and in combination with other cancer treatments. The company is led by President and Chief Executive Officer Arthur Kuan.

View CG Oncology Profile